ReviewClinical and experimental hepatology2017
New directions in hepatitis B therapy research.
Review in Clinical and experimental hepatology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed, 11 citations in OpenAlex.
- Review
- Chronic hepatitis B virus infection in Italy during the twenty-first century: an updated survey in 2019.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2021Article
- HBV Core Promoter Inhibition by Tubulin Polymerization Inhibitor (SRI-32007).Advances in virology · 2020Article
- Hepatitis B and HIV-1 2019 IAS Cure Forum: lessons and benefits from interdisciplinary research.Journal of virus eradication · 2019Article
- Notum attenuates HBV-related liver fibrosis through inhibiting Wnt 5a mediated non-canonical pathways.Biological research · 2019Article
- HIV, HCV and HBV: A Review of Parallels and Differences.Infectious diseases and therapy · 2018Review
- miR-224 suppresses HBV replication posttranscriptionally through inhibiting SIRT1-mediated autophagy.International journal of clinical and experimental pathology · 2018Article
- Evaluation of the inactivation effect of riboflavin photochemical method on duck hepatitis B virus.Experimental and therapeutic medicine · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Chronic hepatitis B treatment is available for a long period, allowing disease control and infection suppression, but it is rarely responsible for HBsAg clearance. None of the drugs available aim at cccDNA, the obstacle in HBV infection eradication. Complications related to CHB, such as liver insufficiency, cirrhosis, and hepatocellular carcinoma are reduced in conditions of good viremia suppression, but still exist even after HBsAg seroclearance, what makes a need for urgent forthcoming of new therapeutics. Recent years brought promising and interesting results of experimental approaches, which are directed against different phases of HBV life cycle, target ccc DNA, or boost, and restore host immune response. Unfortunately, encouraging results
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.